Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Muriel Urwyler

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Cell Death Discovery|April 15, 2025
Selective molecular inhibition of the HDAC6 ZnF-UBP binding domain impairs multiple myeloma cell functionRafael Rincón, Isabel F Coira, Antoine Richieu, et al.
Pharmaceutics|October 29, 2025
Rational Design of Non-Toxic Multidrug Combinations Demonstrates Durable and Hypoxia-Enhanced Efficacy Against Renal Cell CarcinomaValentin Mieville, Jakub Gubala, Mathis Fiault, et al.
Iscience|August 4, 2023
Engineering a versatile and retrievable cell macroencapsulation device for the delivery of therapeutic proteinsJulien Grogg, Remi Vernet, Emily Charrier, et al.
Molecular Therapy. Methods & Clinical Development|September 12, 2022
Immortalized human myoblast cell lines for the delivery of therapeutic proteins using encapsulated cell technologyAurelien Lathuiliere, Remi Vernet, Emily Charrier, et al.
Molecular Therapy. Methods & Clinical Development|October 23, 2023
Erratum: Immortalized human myoblast cell lines for the delivery of therapeutic proteins using encapsulated cell technologyAurelien Lathuiliere, Remi Vernet, Emily Charrier, et al.
Cancer Research Communications|July 23, 2024
A First-in-Human Phase I Clinical Study with MVX-ONCO-1, a Personalized Active Immunotherapy, in Patients with Advanced Solid TumorsRémi Vernet, Eugenio Fernandez, Denis Migliorini, et al.
Experimental Hematology & Oncology|August 31, 2025
Overall survival of recurrent/metastatic head & neck squamous cell carcinoma patients progressing after ≥ 1 line of systemic therapy, treated with MVX-ONCO-1, a novel, first in class cell encapsulation-based immunotherapy: results of SAKK 11/16, a phase IIa trialEugenio Fernandez, Rémi Vernet, Muriel Urwyler, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Cell Death Discovery|April 15, 2025
Selective molecular inhibition of the HDAC6 ZnF-UBP binding domain impairs multiple myeloma cell functionRafael Rincón, Isabel F Coira, Antoine Richieu, et al.
Pharmaceutics|October 29, 2025
Rational Design of Non-Toxic Multidrug Combinations Demonstrates Durable and Hypoxia-Enhanced Efficacy Against Renal Cell CarcinomaValentin Mieville, Jakub Gubala, Mathis Fiault, et al.
Iscience|August 4, 2023
Engineering a versatile and retrievable cell macroencapsulation device for the delivery of therapeutic proteinsJulien Grogg, Remi Vernet, Emily Charrier, et al.
Molecular Therapy. Methods & Clinical Development|September 12, 2022
Immortalized human myoblast cell lines for the delivery of therapeutic proteins using encapsulated cell technologyAurelien Lathuiliere, Remi Vernet, Emily Charrier, et al.
Molecular Therapy. Methods & Clinical Development|October 23, 2023
Erratum: Immortalized human myoblast cell lines for the delivery of therapeutic proteins using encapsulated cell technologyAurelien Lathuiliere, Remi Vernet, Emily Charrier, et al.
Cancer Research Communications|July 23, 2024
A First-in-Human Phase I Clinical Study with MVX-ONCO-1, a Personalized Active Immunotherapy, in Patients with Advanced Solid TumorsRémi Vernet, Eugenio Fernandez, Denis Migliorini, et al.
Experimental Hematology & Oncology|August 31, 2025
Overall survival of recurrent/metastatic head & neck squamous cell carcinoma patients progressing after ≥ 1 line of systemic therapy, treated with MVX-ONCO-1, a novel, first in class cell encapsulation-based immunotherapy: results of SAKK 11/16, a phase IIa trialEugenio Fernandez, Rémi Vernet, Muriel Urwyler, et al.
Pageof 1